Related Experiment Video

Updated: May 12, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials

Peng Li1, Yong Luo, Yi-Ming Chen

  • 1Department of ICU, Peking University Shougang Hospital, Beijing, China.

Heart, Lung & Circulation
|April 23, 2013
PubMed

Insights

B-type natriuretic peptide (BNP)-guided therapy significantly reduces mortality and heart failure rehospitalization in chronic heart failure patients. This approach is particularly effective for those under 70 or with elevated baseline BNP levels.

Area of Science:

  • Cardiology
  • Biomarkers in Heart Failure Management

Background:

  • Plasma B-type natriuretic peptides (BNPs) have been explored to guide chronic heart failure (HF) treatment.
  • Previous randomized controlled trials (RCTs) yielded variable results regarding BNP-guided therapy benefits.
  • A meta-analysis was conducted to ascertain the overall impact of BNP-guided therapy on mortality and HF rehospitalization.

Purpose of the Study:

  • To evaluate the efficacy of B-type natriuretic peptide (BNP)-guided drug therapy in reducing all-cause mortality and heart failure (HF) rehospitalization.
  • To synthesize evidence from randomized controlled trials (RCTs) comparing BNP-guided versus guideline-guided therapy in chronic HF patients.

Main Methods:

  • Systematic search of MEDLINE, EMBASE, and Cochrane Controlled Clinical Trials Register Database for eligible RCTs.
  • Inclusion criteria: RCTs with >40 patients comparing BNP-guided vs. guideline-guided therapy for chronic HF in outpatient settings.
  • Meta-analysis of data from 11 RCTs involving 2414 patients.

Main Results:

  • BNP-guided therapy was associated with a significant reduction in all-cause mortality (RR, 0.83; P=0.035) and HF rehospitalization (RR, 0.75; P=0.004).
  • Meta-regression identified age and baseline BNP as key factors influencing HF rehospitalization.
  • Subgroup analysis showed significantly decreased HF rehospitalization in patients <70 years (RR, 0.45; P=0.000) or with baseline BNP ≥2114 pg/mL (RR, 0.53; P=0.000).

Conclusions:

  • B-type natriuretic peptide (BNP)-guided therapy offers significant benefits over usual care for chronic heart failure (HF) patients.
  • BNP-guided treatment effectively reduces both all-cause mortality and HF rehospitalization.
  • The therapeutic benefits are particularly pronounced in younger patients (<70 years) and those with higher baseline BNP levels.
Abstract

Keywords:
BNPChronic heart failurePrognosisRehospitalisation

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...